Nintedanib Sandoz (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, FGFR and PDGFR—thereby inhibiting signaling pathways that drive fibroblast proliferation, migration and transformation. This results in reduced formation of scar tissue in the lungs and limits angiogenesis that can contribute to disease progression.

The exact dose and dosing schedule of Nintedanib Sandoz are determined by the prescribing clinician based on the patient’s condition, renal and hepatic function, and concomitant therapies. Healthcare professionals should follow the product label and local prescribing guidelines when initiating therapy.

Safety data for Nintedanib during pregnancy and lactation are limited, and the drug is generally not recommended for use in pregnant or nursing women. Women of childbearing potential should use effective contraception throughout treatment and for a suitable period after discontinuation.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Nintedanib Sandoz. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative antifibrotic agent is pirfenidone, which also slows lung function decline in idiopathic pulmonary fibrosis. Nintedanib targets a broader range of tyrosine kinases, while pirfenidone’s mechanism involves modulation of cytokine production and oxidative stress. Choice between them depends on efficacy, tolerability, drug‑interaction profile and individual patient factors.

Nintedanib tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, excessive heat and direct sunlight. Do not store in the bathroom or near a kitchen sink where humidity is high.

Nintedanib is taken orally, usually twice daily, with food to improve tolerability. The tablets should be swallowed whole with a full glass of water. Patients should not crush, split or chew the tablets, and should follow any additional instructions provided by their healthcare professional.

Serious adverse events include hepatotoxicity (significant liver enzyme elevation or liver injury), severe bleeding (especially when combined with anticoagulants), cardiovascular events such as myocardial infarction or stroke, and acute worsening of interstitial lung disease. Patients should report any signs of liver dysfunction, unusual bleeding, chest pain or sudden respiratory decline immediately.

Nintedanib is contraindicated in patients with known hypersensitivity to the active ingredient or any excipients, in those with severe liver impairment, and in individuals who are pregnant or breastfeeding. Caution is also advised for patients with a history of significant bleeding, uncontrolled cardiovascular disease, or active infections.